SAB Bio Receives FDA Fast Track Designation for SAB-142
SAB Bio announced that the FDA granted Fast Track designation to SAB-142, a potential immunotherapy for new-onset Stage 3 type 1 diabetes.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
SAB Biotherapeutics Receives FDA Fast Track Designation for SAB-142
The FDA granted Fast Track designation to SAB-142 for Stage 3 type 1 diabetes.